Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, Taniwaki M. Kuroda J, et al. Among authors: shimura y. Mol Cancer Res. 2010 Jul;8(7):994-1001. doi: 10.1158/1541-7786.MCR-10-0040. Epub 2010 Jun 22. Mol Cancer Res. 2010. PMID: 20571063
Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients.
Yamamoto M, Kuroda J, Uchiyama H, Kobayashi T, Tsutsumi Y, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Matsumoto Y, Shimazaki C, Horiike S, Taniwaki M, Shimazaki C. Yamamoto M, et al. Among authors: shimura y. Leuk Res. 2010 Apr;34(4):e111-2. doi: 10.1016/j.leukres.2009.09.027. Epub 2009 Oct 13. Leuk Res. 2010. PMID: 19828194 No abstract available.
Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M. Kuroda J, et al. Among authors: shimura y. Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27. Int J Hematol. 2010. PMID: 20978877 No abstract available.
Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome.
Mizutani S, Kuroda J, Shimura Y, Kobayashi T, Tsutsumi Y, Yamashita M, Yamamoto M, Ohshiro M, Sasaki N, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Nakamura S, Taniwaki M. Mizutani S, et al. Among authors: shimura y. Acta Haematol. 2011;126(1):8-12. doi: 10.1159/000323565. Epub 2011 Mar 17. Acta Haematol. 2011. PMID: 21411984
Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y, Kobayashi T, Shimura Y, Matsumoto Y, Taki T, Nishida K, Horiike S, Akao Y, Taniwaki M. Sasaki N, et al. Among authors: shimura y. Exp Hematol. 2011 Aug;39(8):817-28.e1. doi: 10.1016/j.exphem.2011.05.002. Epub 2011 May 11. Exp Hematol. 2011. PMID: 21640157 Free article.
Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia.
Yamamoto-Sugitani M, Kuroda J, Ashihara E, Nagoshi H, Kobayashi T, Matsumoto Y, Sasaki N, Shimura Y, Kiyota M, Nakayama R, Akaji K, Taki T, Uoshima N, Kobayashi Y, Horiike S, Maekawa T, Taniwaki M. Yamamoto-Sugitani M, et al. Among authors: shimura y. Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17468-73. doi: 10.1073/pnas.1111138108. Epub 2011 Oct 10. Proc Natl Acad Sci U S A. 2011. PMID: 21987825 Free PMC article.
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Among authors: shimura y. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624
Comprehensive cytogenetic study of primary cutaneous gamma-delta T-cell lymphoma by means of spectral karyotyping and genome-wide single nucleotide polymorphism array.
Yamamoto-Sugitani M, Kuroda J, Shimura Y, Nagoshi H, Chinen Y, Ohshiro M, Mizutani S, Kiyota M, Nakayama R, Kobayashi T, Uchiyama H, Matsumoto Y, Horiike S, Taniwaki M. Yamamoto-Sugitani M, et al. Among authors: shimura y. Cancer Genet. 2012 Sep;205(9):459-64. doi: 10.1016/j.cancergen.2012.05.006. Epub 2012 Jul 21. Cancer Genet. 2012. PMID: 22819381
Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T, Tsutsumi Y, Sakamoto N, Nagoshi H, Yamamoto-Sugitani M, Shimura Y, Mizutani S, Matsumoto Y, Nishida K, Horiike S, Asano N, Nakamura S, Kuroda J, Taniwaki M. Kobayashi T, et al. Among authors: shimura y. Jpn J Clin Oncol. 2012 Nov;42(11):1035-42. doi: 10.1093/jjco/hys148. Epub 2012 Sep 14. Jpn J Clin Oncol. 2012. PMID: 22984125
371 results